

# Anish Thomas Mbbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8757237/publications.pdf>

Version: 2024-02-01

129  
papers

6,469  
citations

70961

41  
h-index

74018

75  
g-index

134  
all docs

134  
docs citations

134  
times ranked

9205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody-drug conjugates for cancer therapy. <i>Lancet Oncology</i> , The, 2016, 17, e254-e262.	5.1	439
2	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1343-1373.	0.8	324
3	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
4	Mesothelin Immunotherapy for Cancer: Ready for Prime Time?. <i>Journal of Clinical Oncology</i> , 2016, 34, 4171-4179.	0.8	244
5	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	5.1	240
6	Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1000-1007.	0.8	206
7	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. <i>Science Translational Medicine</i> , 2013, 5, 208ra147.	5.8	198
8	Targeting Topoisomerase I in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , 2019, 25, 6581-6589.	3.2	184
9	Phase II Clinical Trial of Amatumimab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2014, 20, 5927-5936.	3.2	158
10	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. <i>Cancer</i> , 2014, 120, 3311-3319.	2.0	144
11	Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1447-1457.	0.5	136
12	A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 2601-2606.	0.6	128
13	Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma. <i>JAMA Oncology</i> , 2019, 5, 351.	3.4	127
14	Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1594-1602.	0.8	122
15	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. <i>IScience</i> , 2018, 10, 247-264.	1.9	117
16	Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 191-200.	5.1	111
17	Mutations of epigenetic regulatory genes are common in thymic carcinomas. <i>Scientific Reports</i> , 2014, 4, 7336.	1.6	109
18	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , 2012, 119, 2731-2737.	0.6	108

#	ARTICLE	IF	CITATIONS
19	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	3.3	108
20	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell, 2021, 39, 566-579.e7.	7.7	107
21	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106
22	First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. Journal of Clinical Oncology, 2020, 38, 1824-1835.	0.8	102
23	Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. Frontiers in Oncology, 2015, 5, 113.	1.3	100
24	Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncology, The, 2012, 13, e301-e310.	5.1	99
25	Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. Journal of Thoracic Oncology, 2016, 11, 1993-2005.	0.5	96
26	Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. , 2019, 7, 269.		94
27	New Insights into Understanding the Mechanisms, Pathogenesis, and Management of Malignant Mesotheliomas. American Journal of Pathology, 2013, 182, 1065-1077.	1.9	91
28	Temozolomide in the Era of Precision Medicine. Cancer Research, 2017, 77, 823-826.	0.4	91
29	Scientific Advances and New Frontiers in Mesothelioma Therapeutics. Journal of Thoracic Oncology, 2018, 13, 1269-1283.	0.5	87
30	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Reports, 2020, 33, 108296.	2.9	86
31	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study. Clinical Cancer Research, 2014, 20, 5392-5402.	3.2	83
32	Clinical Response of Live-Attenuated, <i>Listeria monocytogenes</i> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research, 2019, 25, 5787-5798.	3.2	72
33	Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nature Communications, 2021, 12, 3880.	5.8	71
34	High mesothelin expression in advanced lung adenocarcinoma is associated with <i>KRAS</i> mutations and a poor prognosis. Oncotarget, 2015, 6, 11694-11703.	0.8	66
35	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( <i>SLFN11</i> ) Expression with Class I Histone Deacetylase Inhibitors. Clinical Cancer Research, 2018, 24, 1944-1953.	3.2	65
36	Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS ONE, 2016, 11, e0156728.	1.1	64

#	ARTICLE	IF	CITATIONS
37	From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma. <i>Annals of Oncology</i> , 2013, 24, 577-585.	0.6	60
38	Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 261.	1.3	58
39	Biomarkers in Early-Stage Non-Small-Cell Lung Cancer: Current Concepts and Future Directions. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1609-1617.	0.5	54
40	Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. <i>Journal of Thoracic Oncology</i> , 2022, 17, 141-153.	0.5	53
41	Characteristics and Outcomes of Small Cell Lung Cancer Detected by CT Screening. <i>Chest</i> , 2018, 154, 1284-1290.	0.4	52
42	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , 2020, 15, 843-859.	0.5	51
43	Myeloma and Second Primary Cancers. <i>New England Journal of Medicine</i> , 2011, 365, 2241-2242.	13.9	49
44	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8503-8503.	0.8	43
45	Distinctive clinical characteristics of malignant mesothelioma in young patients. <i>Oncotarget</i> , 2015, 6, 16766-16773.	0.8	42
46	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. <i>Science Translational Medicine</i> , 2016, 8, 346fs12.	5.8	40
47	Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 2859-2872.	3.2	40
48	Safety and biodistribution of <sup>111</sup> In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging. <i>Oncotarget</i> , 2015, 6, 4496-4504.	0.8	38
49	Pulmonary lymphangitic carcinomatosis as a primary manifestation of colon cancer in a young adult. <i>Cmaj</i> , 2008, 179, 338-340.	0.9	37
50	Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models. <i>Nature Communications</i> , 2022, 13, 2023.	5.8	36
51	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 828-836.	3.2	35
52	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
53	Tyrosine Kinase Inhibitors in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 589-605.	0.9	32
54	Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. <i>Cancer</i> , 2020, 126, 4936-4947.	2.0	31

#	ARTICLE	IF	CITATIONS
55	Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 567-571.	0.5	28
56	Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Science Translational Medicine, 2020, 12, .	5.8	28
57	Expression of a novel tropomyosin isoform in axolotl heart and skeletal muscle. Journal of Cellular Biochemistry, 2010, 110, 875-881.	1.2	27
58	18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Patients with Thymic Epithelial Tumors. Clinical Cancer Research, 2013, 19, 1487-1493.	3.2	25
59	Are neuroendocrine negative small cell lung cancer and large cell neuroendocrine carcinoma with WT RB1 two faces of the same entity?. Lung Cancer Management, 2019, 8, LMT13.	1.5	25
60	LGL Leukemia and HTLV. AIDS Research and Human Retroviruses, 2010, 26, 33-40.	0.5	24
61	Farletuzumab in lung cancer. Lung Cancer, 2013, 80, 15-18.	0.9	24
62	Colonic Necrosis Due to Oral Kayexalate in a Critically-Ill Patient. American Journal of the Medical Sciences, 2009, 337, 305-306.	0.4	22
63	Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer, 2015, 15, 376.	1.1	22
64	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. Frontiers in Oncology, 2019, 9, 994.	1.3	22
65	Concurrent Molecular Alterations in Tumors With Germ Line Epidermal Growth Factor Receptor T790M Mutations. Clinical Lung Cancer, 2013, 14, 452-456.	1.1	20
66	Response to Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3425-3426.	0.8	19
67	Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement. Journal of Thoracic Oncology, 2012, 7, e29-e31.	0.5	19
68	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers, 2021, 13, 4601.	1.7	19
69	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an exceptional responder lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	0.5	18
70	Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer, 2016, 101, 104-110.	0.9	18
71	DNA-Targeted Precision Medicine; Have We Been Caught Sleeping?. Trends in Cancer, 2017, 3, 2-6.	3.8	18
72	Expression of tropomyosin 2 gene isoforms in human breast cancer cell lines. Oncology Reports, 2016, 35, 3143-3150.	1.2	17

#	ARTICLE	IF	CITATIONS
73	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>JAMA Network Open</i> , 2020, 3, e200032.	2.8	17
74	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers. <i>Chest</i> , 2020, 158, 1723-1733.	0.4	16
75	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	0.6	16
76	Expression of Nkx2.5 in Wild Type, Cardiac Mutant, and Thyroxine-Induced Metamorphosed Hearts of the Mexican Axolotl. <i>Cardiovascular Toxicology</i> , 2009, 9, 13-20.	1.1	15
77	EGFR Mutations in Latinos From the United States and Latin America. <i>Journal of Global Oncology</i> , 2016, 2, 259-267.	0.5	15
78	Characterization and Management of Cardiac Involvement of Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 246-249.	0.5	14
79	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. <i>Translational Lung Cancer Research</i> , 2016, 5, 727-730.	1.3	14
80	Temporal patterns of care and outcomes of non-small cell lung cancer patients in the United States diagnosed in 1996, 2005, and 2010. <i>Lung Cancer</i> , 2017, 103, 66-74.	0.9	14
81	Isolated CNS relapse of CML after bone marrow transplantation. <i>Leukemia Research</i> , 2010, 34, e113-e114.	0.4	12
82	Short Communication: No Evidence of HTLV-3 and HTLV-4 Infection in New York State Subjects at Risk for Retroviral Infection. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1229-1231.	0.5	12
83	Absence of Mutation at the 5'-Upstream Promoter Region of the TPM4 Gene From Cardiac Mutant Axolotl ( <i>Ambystoma mexicanum</i> ). <i>Cardiovascular Toxicology</i> , 2011, 11, 235-243.	1.1	12
84	Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report. <i>Oncology Letters</i> , 2015, 10, 1155-1158.	0.8	12
85	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. <i>Cancer Research Communications</i> , 2022, 2, 503-517.	0.7	12
86	Multiorgan Autoimmune Manifestations Associated with Thymoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e5-e7.	0.5	11
87	Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). <i>Journal of Clinical Oncology</i> , 2014, 32, 7525-7525.	0.8	11
88	Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 475-486.	1.1	10
89	Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation. <i>Clinical Cancer Research</i> , 2020, 26, 2452-2456.	3.2	10
90	Targeting mesothelin in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 36050-36051.	0.8	10

#	ARTICLE	IF	CITATIONS
91	Novel Biologic Therapies for Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2014, 4, 103.	1.3	9
92	Methyl dopa-induced autoimmune haemolytic anaemia revisited. <i>New Zealand Medical Journal</i> , 2009, 122, 53-6.	0.5	9
93	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz010.	1.4	8
94	Adult purpura fulminans associated with non-steroidal anti-inflammatory drug use. <i>Journal of Postgraduate Medicine</i> , 2011, 57, 145.	0.2	8
95	Translational research: A patient-centered approach to bridge the valley of death. <i>Cancer Cell</i> , 2022, 40, 565-568.	7.7	8
96	Thymic epithelial tumors and metastasis to the brain: a case series and systematic review. <i>Translational Lung Cancer Research</i> , 2017, 6, 588-599.	1.3	7
97	Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 7565-7565.	0.8	7
98	Megakaryocyte Potentiating Factor as a Predictive Biomarker for Therapies Against Malignant Mesothelioma. <i>JCO Precision Oncology</i> , 2018, 2018, 1-16.	1.5	6
99	Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer. <i>journal of applied laboratory medicine, The</i> , 2018, 3, 166-177.	0.6	6
100	A phase (Ph) I/II study of belinostat (Bel) in combination with cisplatin, doxorubicin, and cyclophosphamide (PAC) in the first-line treatment of advanced or recurrent thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7103-7103.	0.8	6
101	Immunotherapy for non-small-cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1061-1064.	1.4	5
102	Phase II study of cixutumumab (IMC-A12) in thymic malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7033-7033.	0.8	5
103	Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e871-e875.	0.9	4
104	<sup>18</sup> F-FDG PET Assessment of Malignant Pleural Mesothelioma: Total Lesion Volume and Total Lesion Glycolysis—The Central Role of Volume. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1570-1575.	2.8	4
105	Custom (Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small) Tj ETQq1 1 0.784314 rgBT /Overl	0.8	4
106	Should anti-mesothelin therapies be explored in lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 677-679.	1.1	3
107	Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005678.	0.5	3
108	CDK7 Inhibition Synergizes with Topoisomerase I Inhibition in Small Cell Lung Cancer Cells by Inducing Ubiquitin-Mediated Proteolysis of RNA Polymerase II. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1430-1438.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). , 2015, 3, .		2
110	CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2016, 34, 8558-8558.	0.8	2
111	Small cell lung cancer: Why has it become an orphan disease?. Journal of Clinical Oncology, 2015, 33, 7578-7578.	0.8	2
112	Osteopetrosis. Postgraduate Medical Journal, 2009, 85, 250-250.	0.9	1
113	“Pseudocavitation” in Thymic Carcinoma During Treatment with Sunitinib. Journal of Thoracic Oncology, 2013, 8, 511-512.	0.5	1
114	Humoral and Cellular Immune Dysregulation and Lung Cancer. , 2018, , 137-142.e3.		1
115	Replication Stress Defines Distinct Molecular Subtypes Across Cancers. SSRN Electronic Journal, 0, , .	0.4	1
116	Roots and routes of resistance. Science Translational Medicine, 2016, 8, .	5.8	1
117	“Thumbprinting”™. Internal Medicine Journal, 2010, 40, 666-666.	0.5	0
118	Reply to A. Stenzinger et al. Journal of Clinical Oncology, 2015, 33, 2824-2824.	0.8	0
119	Immunotherapeutic Approaches to Mesothelioma. Current Cancer Research, 2017, , 347-357.	0.2	0
120	Reply to Yan et al.. Journal of Thoracic Oncology, 2019, 14, e245-e246.	0.5	0
121	Lenvatinib for thymic carcinomas. Lancet Oncology, The, 2020, 21, 745-746.	5.1	0
122	Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases. Journal of Thoracic Oncology, 2020, 15, e25-e27.	0.5	0
123	More precision in lung cancer therapy. Science Translational Medicine, 2015, 7, .	5.8	0
124	Genes and lung cancer: Stop YAPping!. Science Translational Medicine, 2015, 7, .	5.8	0
125	Small cell lung cancer in profile. Science Translational Medicine, 2015, 7, .	5.8	0
126	Basket trials: Making sense of context. Science Translational Medicine, 2015, 7, .	5.8	0



#	ARTICLE	IF	CITATIONS
127	Lung cancer: A sanguine approach. Science Translational Medicine, 2015, 7, .	5.8	0
128	CREBBP-mutated cancers HAT-tricked. Science Translational Medicine, 2015, 7, .	5.8	0
129	No lung cancer left behind. Science Translational Medicine, 2016, 8, .	5.8	0